English, Article edition: Cost Analysis of 2 Empiric Antibacterial Regimens Containing Glycopeptides for the Treatment of Febrile Neutropenia in Patients with Acute Leukaemia Giampaolo Bucaneve; Francesco Menichetti; Albano Del Favero

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119148
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Analysis of 2 Empiric Antibacterial Regimens Containing Glycopeptides for the Treatment of Febrile Neutropenia in Patients with Acute Leukaemia
Author
  • Giampaolo Bucaneve
  • Francesco Menichetti
  • Albano Del Favero
Physical Description
  • article
Notes
  • Objective: Patients with cancer-associated neutropenia are at high risk of developing severe infections which can be fatal if treatment is not promptly administered. For this reason, fever is treated as soon as possible with broad spectrum antibacterial therapy. The objective of this study was to conduct a cost analysis in Italy comparing 2 empiric glycoprotein-containing antibacterial regimens for the treatment of febrile neutropenia in patients with acute leukaemia. Design and setting: A retrospective cost analysis was conducted, using the records of 527 febrile neutropenic patients with acute leukaemia who participated in an 18-month multicentre (29 Italian haematological units) randomised trial during 1991. All patients received either of the following 2 empiric intravenous regimens, each containing 3 antibacterial agents: ceftazidime (2g, 3 times daily) and amikacin (15 mg/​kg/​day, in 3 separate doses) plus teicoplanin (6 mg/​kg, in a single dose) or vancomycin (30 mg/​kg/​day, in 2 separate doses). Economic analyses were carried out from a hospital perspective. Only the direct costs per patient, i.e. mean antibacterial treatment and management cost, mean overall treatment failure cost and mean cost of adverse effects, were included. Main outcome measures and results: No differences were found in the clinical response, defined as the improvement in the rate of fever or infection (if documented), between the 2 regimens. However, tolerability, defined as the incidence of adverse effects probably or definitely related to the assigned treatment, was reported to be better with the teicoplanin- rather than the vancomycin-containing regimen. Conclusions: This retrospective cost analysis showed that despite the higher acquisition cost of teicoplanin relative to vancomycin, the lower incidence of adverse effects associated with teicoplanin and its ease of administration (single daily dose) resulted in equivalent overall treatment costs between teicoplanin- and vancomycin-containing regimens.
  • Pharmacoeconomics, Cost-analysis, Ceftazidime, Amikacin, Teicoplanin, Vancomycin, Immunocompromised-infections, Neutropenia, Antibacterials, Leukaemia
  • RePEc:wkh:phecon:v:15:y:1999:i:1:p:85-95
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment